Next Article in Journal
Bioelectric Applications for Treatment of Melanoma
Next Article in Special Issue
The Enigmatic Roles of Caspases in Tumor Development
Previous Article in Journal
Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
Previous Article in Special Issue
The Role of Macrophage Migration Inhibitory Factor (MIF) in Ultraviolet Radiation-Induced Carcinogenesis
Article Menu

Export Article

Open AccessReview
Cancers 2010, 2(3), 1717-1730;

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
Department of Pathology, Tohoku University Hospital, Sendai, Japan
Computational Biology Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan
Author to whom correspondence should be addressed.
Received: 23 August 2010 / Revised: 14 September 2010 / Accepted: 15 September 2010 / Published: 17 September 2010
(This article belongs to the Special Issue Cell Death and Cancer)
Full-Text   |   PDF [526 KB, uploaded 17 September 2010]   |  


5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a continuous intravenous infusion. Recent clinical chemotherapy studies have shown that several of the regimens with oral 5-FU drugs are not inferior compared to those involving continuous 5-FU infusion chemotherapy, and it is probable that in some regimens continuous 5-FU infusion can be replaced by oral 5-FU drugs. Historically, both the pharmaceutical industry and academia in Japan have been involved in the development of oral 5-FU drugs, and this review will focus on the current knowledge of 5-FU anabolism and catabolism, and the available information about the various orally-administrable 5-FU drugs, including UFT, S-1 and capecitabine. Clinical studies comparing the efficacy and adverse events of S-1 and capecitabine have been reported, and the accumulated results should be utilized to optimize the treatment of cancer patients. On the other hand, it is essential to elucidate the pharmacokinetic mechanism of each of the newly-developed drugs, to correctly select the drugs for each patient in the clinical setting, and to further develop optimized drug derivatives. View Full-Text
Keywords: 5-FU metabolism; cell death; colon cancer; oral 5-FU drugs 5-FU metabolism; cell death; colon cancer; oral 5-FU drugs

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Miura, K.; Kinouchi, M.; Ishida, K.; Fujibuchi, W.; Naitoh, T.; Ogawa, H.; Ando, T.; Yazaki, N.; Watanabe, K.; Haneda, S.; Shibata, C.; Sasaki, I. 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs. Cancers 2010, 2, 1717-1730.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top